New data from the TULIP-Plus observational registry revealed that Saphnelo (anifrolumab) significantly slowed the accrual of organ damage in systemic lupus erythematosus (SLE) over 18 months. The study followed 324 patients across academic and community settings, assessing change in SDI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index). Compared to historical matched cohorts, Saphnelo-treated patients had 40% fewer new organ complications. Most notable reductions were in renal, CNS, and cardiovascular systems. These data confirm the long-term benefits of type I interferon inhibition and support earlier treatment initiation. No new safety signals emerged; the most common adverse events remained mild infections. This real-world evidence complements RCT data and may drive payer and physician confidence in early SLE biologic use.

Citation: https://www.astrazeneca.com/media-centre/press-releases/2025/saphnelo-real-world-data-show-organ-protection.html

Implication: These results support Saphnelo as a disease-modifying agent in SLE, with real-world relevance.